Arterial Stiffness Mapping A Better Navigation to Ithaca?∗ by Protogerou, Athanase D. et al.
Journal of the American College of Cardiology Vol. 63, No. 17, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2014.01.044EDITORIAL COMMENTArterial Stiffness
Mapping
A Better Navigation to Ithaca?*
Athanase D. Protogerou, MD,y
Theodoros G. Papaioannou, PHD,z
Charalambos Vlachopoulos, MDx
Athens, Greece
Arterial stiffening is the hallmark of normal vascular ag-
ing, and early acceleration of the stiffening process rep-
resents 1 of the major pathologies of the cardiovascular
system (1,2). During the last 50 years, thanks to the
development of easy to use and reasonably reproducible
noninvasive methods to measure arterial stiffness (3), the
extensive clinical investigation of the human arterial elastic
properties led to major advancements in the understand-
ing of cardiovascular disease (CVD) and particularly the
(patho)physiology of arterial hypertension (1,2).See page 1739Several indexes of arterial stiffness have been validated so
far, each providing a different measure of local, segmental, or
systemic stiffness (3). The carotid-to-femoral (cf) pulse wave
velocity (PWV), a measure of segmental stiffness from the
ascending aorta to the femoral artery, is recommended as the
gold standard to evaluate arterial stiffness in clinical practice
(3–5). It fulﬁlls most of the stringent criteria for a biomarker
to be implemented in clinical practice (6). It has a proof of
concept (1,5) differing between subjects with and without
outcomes (1,5). It predicts risk in prospective studies and has
additive predictive value regarding mortality and CVD
events in addition to established CVD scores. An increase of
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relevant to the contents of this paper to disclose.15%, and 15% for total CVD events, CVD mortality, and
all-cause mortality, respectively (7,8). Importantly, it
reclassiﬁes the risk of the subjects in intermediate risk (i.e.,
of those in particular need of better CVD risk stratiﬁcation)
by 13% (9). From a practical standpoint, the technique is
noninvasive, it is user- and patient-friendly, and cost is
currently moderate and is further decreasing as its applica-
tion is widely spreading. Finally, normal and reference values
derived from a large population of more than 16,500 in-
dividuals are now available (10).
Therefore, and rightfully so, the recent 2013 European
Society of Hypertension/European Society of Cardiology
Guidelines for the Management of Arterial Hypertension
(5) recommend the assessment of cfPWV for the detec-
tion of subclinical organ damage in hypertensive in-
dividuals by using the 10 m/s value for the low-risk limit
(when the cf distance is assessed as 80% of the direct
distance between the 2 arterial sites) (Class IIa, Level of
Evidence: B) (4,5).
However, the elastic properties of the arterial tree are not
uniform; some arteries are predominantly of elastic nature
(aorta, carotid), whereas others are muscular (brachial) or
mixed (femoral). Furthermore, the arteries are affected to a
different degree by atheromatosis or arteriosclerosis, and
they have site-speciﬁc physiological consequences. These
facts advance the hypothesis that a judiciously selected
“multiregional mapping” of the human arterial system’s
elastic properties might provide a holistic approach to CVD
event prediction.
In this issue of the Journal, van Sloten et al. (11) provide
momentum, within the context of limitations that were well
discussed by the authors, for this multisite approach. By
performing a comprehensive evaluation of local (brachial,
carotid, femoral), segmental (aortic), and systemic arterial
compliance, they showed that after adjusting for known
CVD confounders, local carotid and femoral arterial stiff-
ness indexes were associated, independently from each
other as well as from cfPWV, with both major evaluated
outcomes (all-cause mortality and CVD events). The data
were derived from a post-hoc analysis of almost 600 par-
ticipants of the Hoorn study (a prospective, population-
based cohort including by design 50% individuals with
insulin resistance) who were followed up for more than 7
years. The particular strength of this study is that it deals
with all of these indexes within the same cohort of patients
and that it provides for the ﬁrst time data on the predictive
ability of local compliance at the femoral and brachial
artery.
One main ﬁnding of the study (11) was that the elastic
properties of the brachial artery do not provide effective
CVD prediction in the general population. This ﬁts well
with the pathophysiogical background of this predominantly
muscular artery that has a relatively small (compared to the
elastic arteries) lifelong vascular senescence range (1,12–14).
Moreover, the anatomical situation of the brachial artery has
“too little to do” with the vital organs (heart, brain, kidney),
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1749and thus, local stiffening has poor impact on them. Should
we then disregard completely any study of this artery? In an
interesting dissection of their results, the authors showed
that, in subjects with impaired glucose metabolism, lower
brachial elasticity was associated with CVD events. This
highlights a frequently neglected aspect of arterial stiffness:
the “disease”-speciﬁc importance of each vascular territory.
To further support this notion, the same research group has
shown that the relative stiffening impact of impaired glucose
status is higher in the muscular brachial artery than in the
elastic aorta (15).
The case was somewhat different with the other local
stiffness indexes (11). Both carotid and femoral stiffness,
after adjusting for classical CVD risk factors and inde-
pendently from each other, were predictors of CVD events.
This is a novel and important step forward. The next
mandatory action is to show whether these indexes can
discriminate, calibrate, and reclassify individuals at CVD
risk beyond the established predictive models and cfPWV.
The present study (11) did not provide such data due to
insufﬁcient power. Finally, as a self-fulﬁlling prophecy,
these local indexes could show a preferential association
between site-speciﬁc arterial stiffening and CVD subtypes
(e.g., carotid artery stiffening and stroke; aortic stiffening
and myocardial infarction). This subanalysis was not
feasible in the present study due to the limited number of
events, but further investigation in this direction is
worthwhile.
What about the practicality of a multisite arterial stiffness
mapping approach? Major technological advances are in
process. New methods (16–18), improved algorithms (19),
and novel devices (20) are emerging to the extent of
allowing local PWV assessment (18) and 24-h PWV
monitoring (20). Such advancements will certainly further
improve the clinical impact of stiffness indexes and the
practicality of such an approach. On the other hand,
extreme caution on the physiological reasoning and metic-
ulous validation of all new methods and devices is
warranted.
For the time being, cfPWV is a robust clinical tool for
selected clinical use, whereas further clinical applications,
such as the identiﬁcation of individuals at higher risk to
develop hypertension (21), should be evaluated. Most
importantly, high cfPWV is related to low blood pressure
response to antihypertensive drugs (22), and its reduction
is associated with higher survival rates (23); thus, it might
serve as a guide for blood pressure–lowering strategies.
This will be elucidated by ongoing randomized studies
(24).
The present study by van Sloten et al. (11) dynamically
puts additional arterial sites on the map. Although further
research must address the questions raised herein, a wisely
applied “arterial stiffness mapping” may ultimately prove to
be a better navigation to the “Ithaca” of individualized risk
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